<DOC>
	<DOCNO>NCT00003412</DOCNO>
	<brief_summary>RATIONALE : Interleukin-12 may kill tumor cell stop blood flow tumor stimulate person 's white blood cell kill breast cancer cell . PURPOSE : Phase I trial study effectiveness interleukin-12 treat woman metastatic breast cancer receive high-dose chemotherapy peripheral stem cell transplantation .</brief_summary>
	<brief_title>Interleukin-12 Treating Women With Metastatic Breast Cancer Who Have Received High-Dose Chemotherapy Peripheral Stem Cell Transplantation</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxic effect profile maximum tolerate dose interleukin-12 ( rhIL-12 ) woman advance breast cancer undergone high dose chemotherapy stem cell rescue . II . Determine effect rhIL-12 cellular humoral immune system follow high dose chemotherapy . III . Explore effect treatment failure rhIL-12 high dose chemotherapy stem cell rescue . OUTLINE : This dose escalation study interleukin-12 ( rhIL-12 ) . RhIL-12 therapy begin 3-5 week discharge chemotherapy/stem cell transplant hospitalization 2-3 week completion posttransplant radiation . Patients receive rhIL-12 subcutaneously twice week 12 consecutive week . Treatment continue absence disease progression unacceptable toxicity . Cohorts 3-6 patient treat dose level rhIL-12 . The maximum tolerate dose define dose 1 6 patient experience dose limit toxicity . Patients follow every 2 month treatment . PROJECTED ACCRUAL : Approximately 6-35 patient accrue study within 1-2 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Interleukin-12</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven stage IV breast cancer present primary metastatic disease recurrence initial diagnosis localize disease Enrollment protocol high dose chemotherapy stem cell rescue use `` STAMP V '' regimen ( cyclophosphamide , thiotepa , carboplatin ) No enrollment research transplant protocol whose primary endpoint response duration recovery time toxic effect No brain CNS metastases Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 60 Sex : Female Menopausal status : Not specify Performance status : Karnofsky 80100 % Life expectancy : At least 6 month Hematopoietic : WBC least 3,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time normal SGOT great 2.5 time normal Renal : Creatinine great 1.8 mg/dL Creatinine clearance least 60 mL/min Cardiovascular : Systolic ejection fraction least 50 % No significant cardiovascular disease cardiac arrhythmia require drug device intervention Pulmonary : DLCO FEV1 great 50 % Neurologic : No significant peripheral neuropathy CNS disease Other : Fertile patient must use effective contraception Not pregnant lactate Not HIV positive No concurrent active infection require IV antibiotic therapy No significant gastrointestinal bleeding uncontrolled peptic ulcer disease No history inflammatory bowel disease No clinically significant autoimmune disease No serious illness medical condition PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : See Disease Characteristics No concurrent chemotherapy Endocrine therapy : No concurrent corticosteroid Radiotherapy : No concurrent radiotherapy Surgery : Not specify Other : At least 4 week since investigational drug No concurrent investigational drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2001</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>